Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
Erwan Bézard(Centre National de la Recherche Scientifique), Pierre Sokoloff(Inserm), U Mach(Goethe University Frankfurt), Thomas Boraud(Centre National de la Recherche Scientifique), Holger Stark(Heinrich Heine University Düsseldorf), Ludovic Leriche(Inserm), Christian E. Gross(Centre National de la Recherche Scientifique), Sandrine Ferry(Inserm)
Cited by 381
Related Papers
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
|Pharmacological Reviews|2015|558
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
|Journal of Medicinal Chemistry|2018|476
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472